Mark Alvino Sells 13,500 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Mark Alvino sold 13,500 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $5.23, for a total value of $70,605.00. Following the sale, the director owned 48,752 shares of the company’s stock, valued at $254,972.96. This represents a 21.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Mark Alvino also recently made the following trade(s):

• On Thursday, November 13th, Mark Alvino sold 15,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $4.74, for a total value of $71,100.00.

Abeona Therapeutics Price Performance

Shares of Abeona Therapeutics stock remained flat at $5.31 on Wednesday. 1,194,794 shares of the stock traded hands, compared to its average volume of 1,277,038. The firm has a 50 day moving average of $5.04 and a 200-day moving average of $5.64. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54. The firm has a market cap of $287.75 million, a PE ratio of 4.32 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 9.53 and a current ratio of 9.74.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, equities analysts predict that Abeona Therapeutics Inc. will post -1.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ABEO shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a research note on Monday, October 13th. Weiss Ratings lowered shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 24th. Finally, Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Institutional Investors Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. increased its stake in shares of Abeona Therapeutics by 14.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock valued at $17,455,000 after purchasing an additional 381,357 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Abeona Therapeutics by 3.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,602,901 shares of the biopharmaceutical company’s stock worth $13,743,000 after purchasing an additional 95,878 shares in the last quarter. Boone Capital Management LLC purchased a new stake in shares of Abeona Therapeutics in the 2nd quarter worth approximately $7,126,000. Geode Capital Management LLC increased its position in Abeona Therapeutics by 129.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock valued at $6,282,000 after buying an additional 623,243 shares in the last quarter. Finally, Kennedy Capital Management LLC increased its position in Abeona Therapeutics by 56.4% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,050,863 shares of the biopharmaceutical company’s stock valued at $5,549,000 after buying an additional 378,860 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.